Manufacturer halts distribution of generic Zantac after cancer-causing impurity discovery
When the FDA issued a bulletin alerting everyone to the presence of a possible cancer-causing impurity in the popular heartburn drug marketed as Zantac, the administration stopped short of telling people to stop taking the popular drugs. Now, in the wake of that news, shipments of a generic version of the drug are being halted.
In its release, the FDA noted that samples of the drug known as ranitidine, also sold under the brand name Zantac, tested positive for a potentially cancer-causing agent called N-nitrosodimethylamine, or NDMA. Levels of the carcinogen weren't alarmingly high, but its presence alone was enough to warrant a public alert.
BGR Top Deals:
- Amazon is blowing out SD cards, microSDs, and flash drives at rock-bottom prices, today only
- This $14 device will put an end to slow-downs and pixelation on your Fire TV Stick
Trending Right Now:
- This iPhone 11 Night mode photo sample is going to blow your mind
- Apple Watch Series 5 review roundup: There’s (still) no other smartwatch like it
- Apple just released iOS 13.1 beta 4
Manufacturer halts distribution of generic Zantac after cancer-causing impurity discovery originally appeared on BGR.com on Wed, 18 Sep 2019 at 16:20:11 EDT. Please see our terms for use of feeds.